PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development

If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.

Read more...
 
Three Reasons to Buy BSGM Today

With the interest rate concerns behind us, it is time to profile a stock that has such profoundly strong milestones in ahead in 2016 that we believe it will jump from $1 to $5.

Read more...
 
Ground Floor Mobile Gaming Stock

Today we are introducing a new idea---a ground floor opportunity, really. One of the fastest growing industries is the mobile gaming market and Pocket Games, Inc. (OTC – PKGM) has a targeted acquisition strategy and very clever approach which has already begun to bear fruit.

Read more...
 
PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers

PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.

Read more...
 
This $1 NASDAQ Stock Is Worth $5

The market may be flirting with year highs but this incredibly undervalued stock has not yet made its move, which we think could occur before year-end. Here’s why, as outlined in a new sponsored research update:

Read more...
 
Faster Approval Ahead for PharmaCyte

Recent and pending events infer that the road to approval and marketing of Pharmacyte's flagship pancreatic cancer treatment has been dramatically shortened, potentially leading to a banner year 2016 for PharmaCyte shareholders.

Read more...
 
Next Big Cardiac Medical Device Stock

This low valuation medical device company is set to transform its segment of the $3 billion electrophysiology (EP) marketplace. EP studies are used in conjunction with cardiac ablation procedures for patients suffering from atrial fibrillation (AF) and other conditions. The Company’s flagship platform fulfills an unmet need by enhancing the efficacy and diagnostic value of EP studies. Moreover, it reduces the frequency of and the time it takes to complete EP studies used in cardiac ablation procedures.

Read more...
 
PMCB May Be On The Verge Of A Major Breakthrough In Diabetes Treatment

PMCB's approach to diabetes therapy could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them.

Read more...
 
PharmaCyte Cancer Treatment Approval Odds and Timing Just Moved Much Higher

Last week was an incredible week for PharmaCyte Biotech (OTC – PMCB), which prompted us to issue a new research update. Major industry and company news released last week should take investor sentiment and the stock to a new level regarding the potential and timing of FDA approval for PharmaCyte’s pancreatic cancer treatment for patients with locally advanced pancreatic cancer. 

Read more...
 
PharmaCyte Biotech’s Cell Encapsulation Technology at the Forefront of Future Diabetes Treatments

PharmaCyte Biotech’s Cell Encapsulation Approach to Treat Diabetes Could Prove Superior to Other Encapsulation Techniques 

Following decades of failed research, a great deal of attention and funding have recently turned toward utilizing encapsulation techniques to treat Type 1 diabetes (T1D), including the approach championed by PharmaCyte Biotech (OTCQB – PMCB - $0.1152 – Spec Buy), which in turn, is likely to drive clinical and investor interest in the Company.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 36